2011
1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism
Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G. 1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism. Biological Psychiatry 2011, 71: 1022-1025. PMID: 22169441, PMCID: PMC3660962, DOI: 10.1016/j.biopsych.2011.11.006.Peer-Reviewed Original ResearchConceptsMedial prefrontal cortexSubanesthetic dosesAcute effectsNeurotransmitter cyclingMagnetic resonance spectroscopy measuresMPFC of ratsPotential physiological processesAntidepressant-like propertiesSaline-treated animalsAmino acid neurotransmittersHippocampus of ratsDose of ketamineEffects of ketamineGlial energy metabolismMPFC levelsGlutamate releaseKetamine effectsΓ-aminobutyric acidGlial metabolismKetaminePrefrontal cortexEnrichment of glutamateVivo studiesEnergy metabolismRatsThe stressed synapse: the impact of stress and glucocorticoids on glutamate transmission
Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nature Reviews Neuroscience 2011, 13: 22-37. PMID: 22127301, PMCID: PMC3645314, DOI: 10.1038/nrn3138.Peer-Reviewed Original ResearchConceptsGlutamate releaseGlutamate transmissionAcute stressCognitive functionPrefrontal cortexPrefrontal cortex-dependent cognitive functionsGlutamatergic synaptic transmissionLimbic brain areasGlutamatergic neurotransmitter systemChronic stress exposureUnmet therapeutic needMonoaminergic mechanismsNeurochemical mediatorsCertain cognitive functionsLimbic regionsPrimary neurotransmitterNMDA receptorsGlutamate receptorsNeurotransmitter systemsPharmacological interventionsSynaptic transmissionGlutamate synapseMaladaptive changesBrain areasBrain tissue
2008
Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole
Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Molecular Psychiatry 2008, 15: 501-511. PMID: 18825147, PMCID: PMC3347761, DOI: 10.1038/mp.2008.106.Peer-Reviewed Original ResearchMeSH KeywordsAcetatesAnimalsAvoidance LearningBehavioral SymptomsDepressionDisease Models, AnimalFood PreferencesGene Expression RegulationGlial Fibrillary Acidic ProteinGlutamic AcidIsotopesMagnetic Resonance SpectroscopyMaleNeurogliaNeuroprotective AgentsPrefrontal CortexRadionuclide ImagingRatsRats, Sprague-DawleyRiluzoleRNA, MessengerStatistics, NonparametricStress, PsychologicalSucroseSweetening AgentsConceptsChronic unpredictable stressPrefrontal cortexGlial dysfunctionGlial functionBehavioral deficitsDrug riluzoleOpen-label clinical trialMRNA expressionAmino acid neurotransmissionAntidepressant drug developmentDepressive-like behaviorPathophysiology of depressionEffects of riluzoleGlial cell metabolismMajor depressive disorderRat prefrontal cortexGFAP mRNA expressionProtein mRNA expressionNeurotransmitter system abnormalitiesGlia pathologyGlial pathologyRiluzole treatmentAntidepressant actionChronic treatmentGlutamate releaseTargeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 2008, 7: 426-437. PMID: 18425072, PMCID: PMC2715836, DOI: 10.1038/nrd2462.Peer-Reviewed Original ResearchConceptsGlutamatergic systemMood disordersAntidepressant effectsNMDA antagonistsDouble-blind placebo-controlled crossover studyTreatment-resistant major depressive disorderPlacebo-controlled crossover studyGlutamate release inhibitorSignificant antidepressant effectNMDA receptor expressionRecurrent mental illnessSingle intravenous doseMajor depressive disorderPotential novel therapeuticsGlutamatergic abnormalitiesCrossover studyGlutamate releaseIntravenous doseMood stabilizersDepressive disorderReceptor expressionReceptor modulatorsEvidence of alterationsCerebrospinal fluidAMPA potentiators